The vascular endothelial growth factor (VEGF) family of growth factors are important modulators of the angiogenesis process, mediating vascular permeability and the formation of new blood vessels from the existing vasculature. 1 Discovery of the involvement of VEGF in a number of pathologic conditions, including neovascular age-related macular degeneration (AMD), diabetic retinopathy, and cancer, has prompted the development of several anti-VEGF therapies for the treatment of these conditions.
the second eye becoming affected. Therefore, early detection, diagnosis, and treatment of CNV is essential to maximise the preservation of central vision, minimise the risk of blindness, and maintain patients' quality of life. 6 
Prevalence
The Rotterdam Study assessed the prevalence of agerelated maculopathy in an elderly population in the Netherlands. 7 Prevalence of neovascular AMD was 1.1% overall (0.8% in men and 1.2% in women), whereas prevalence of atrophic AMD was 0.6% (equally prevalent in men and women). Prevalence of AMD increased with age, rising to 11% in people aged 85 years or older. 7 As the population of Europe ages, an increase in the number of patients with AMD can be expected. A recent Swiss study has estimated that there will be a 2.5-fold increase in the number of late AMD cases in Switzerland by 2050, with numbers rising from 37 200 cases in 2005 to 52 500 cases in 2020 and 93 200 cases in 2050. 8 
Treatment Options for AMD
Until the recent introduction of anti-VEGF therapy, treatment options for neovascular AMD were limited. In the 1980s, the Macular Photocoagulation Study Group reported that laser treatment of extrafoveal choroidal neovascular lesions was benefi cial in delaying loss of vision for at least 5 years. 9, 10 The introduction of photodynamic therapy (PDT) with verteporfi n in Europe in 2000 and Japan in 2004 further expanded treatment options for AMD. The Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study (TAP) reported that after 2 years of treatment, 53% of patients treated with verteporfi n plus PDT lost fewer than 15 letters, compared with 38% of patients treated with placebo plus PDT. Subgroup analyses revealed that the benefi ts of PDT with verteporfi n were concentrated primarily in patients with classic CNV. 
Anti-VEGF Treatment
The exact mechanisms of the pathogenesis of neovascular AMD are not fully understood; however, increased expression of VEGF in the optic nerve and retina is known to precede retinal neovascularisation.
12 VEGF mRNA levels have been shown to be upregulated in both clinical and experimental studies of CNV, [13] [14] [15] and the introduction of VEGF to healthy eyes mimics the neovascularisation that is observed during the disease process.
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Pegaptanib (Macugen)
Pegaptanib is a specifi c nucleic acid ligand (aptamer) that binds to VEGF165, the most abundant of the human VEGF isoforms, and thereby inhibits interaction with its receptors. Pegaptanib is licensed in Europe for the treatment of neovascular AMD and is administered by intravitreal injection every 6 weeks for at least 2 years. 19 The VEGF Inhibition Study in Ocular Neovascularization (VISION) clinical trials investigated the safety and effi cacy of pegaptanib for the treatment of neovascular AMD in 1190 patients over 2 years. [20] [21] [22] One trial enrolled patients from the United States and Canada, and the other trial enrolled patients from Europe, Israel, Australia, and South America. At baseline, patients were randomised to one of four treatment groups (0.3, 1, or 3 mg pegaptanib, or sham), with treatment administered every 6 weeks for 54 weeks (a total of nine treatments). Thereafter, patients receiving pegaptanib were randomised to either continue treatment for a second year or cease treatment. To minimise the number of patients receiving sham treatment for 2 years, at year 1 the sham group was randomised to continuing sham injections, no treatment, or one of the three pegaptanib doses. The primary effi cacy endpoint was the proportion of patients losing fewer than 15 letters of visual acuity at week 54. The aims of the second year of study were to assess the safety of the 2-year treatment with pegaptanib, assess the relative benefi t of 2-year treatment over 2 years of usual care, and determine whether a second year of treatment resulted in additional benefi ts beyond the fi rst year.
In a combined analysis of the data from both trials, all three doses of pegaptanib were effi cacious in preventing loss of vision compared with sham injections across all CNV subtypes; 20 70%, 71%, and 65% of patients receiving 0.3, 1, and 3 mg pegaptanib, respectively, experienced a loss of fewer than 15 letters of visual acuity at week 54, compared with 55% of patients receiving sham injections (P < 0.001, P < 0.001, and P = 0.03, respectively). In addition, 33%, 37%, and 31% of patients receiving 0.3, 1, and 3 mg pegaptanib, respectively, maintained their vision or gained vision, compared with 23% of patients receiving sham injections (P = 0.003, P < 0.001, and P = 0.02, respectively). 20 Figure 1 shows the mean change in visual acuity from baseline to week 54.
Analysis of the 2-year VISION trial data revealed that mean visual acuity was maintained in patients receiving 0.3 mg pegaptanib, and the proportion of patients losing fewer than 15 letters of visual acuity from week 54 to week 102 was half that (7%) of those who were assigned to 2 years of sham injections or randomised to stop treatment after 1 year (14%). 21 In patients who had a visual acuity of 20/200 or better at baseline, those who were treated with continuous 0.3 mg pegaptanib were less likely to progress to legal blindness in year 2; 34% of patients at week 54 and 35% of patients at week 102 in this group had a visual acuity of 20/200 or worse in the study eye. In contrast, 24% of patients assigned to discontinue treatment with pegaptanib at week 54, and 47% of patients in the sham injection group, had a visual acuity of 20/200 or worse at week 54, increasing to 38% and 55%, respectively, at week 102. 21 Endophthalmitis (1.3%), traumatic injury to the lens (0.7%), and retinal detachment (0.6%) were the most serious injection-related adverse events (AEs) reported in the fi rst year, with two-thirds of cases of endophthalmitis following protocol violations. The authors concluded that these rates were consistent with data in the literature for intravitreous injections and, therefore, the risks associated with the intraocular injection of pegaptanib were probably no worse than those associated with other intraocular treatments. 20 However, a protocol amendment resulted in no reports of endophthalmitis or traumatic injury to the lens in year 2. 22 The 2-year results also showed that there was no evidence of an increase in AEs associated with systemic VEGF inhibition, such as hypertension, thromboembolic events, or serious haemorrhagic events. 22 An additional 1-year systemic safety study has confi rmed that there is no evidence of systemic VEGF inhibition even at doses up to tenfold the approved 0.3 mg. 23 
Ranibizumab (Lucentis)
Ranibizumab is a humanised monoclonal antibody Fab fragment that inhibits all fi ve human isoforms of VEGF-A, and was specifi cally designed for the treatment of neovascular AMD. 24 The MARINA (Minimally Classic/Occult Trial of the Anti-VEGF Antibody to Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration) study investigated ranibizumab for the treatment of minimally classic or occult with no classic CNV associated with AMD at 96 sites in the United States. 25 A total of 716 patients were randomised equally to receive 24 monthly intravitreal injections of 0.3 or 0.5 mg ranibizumab, or sham injections. The primary effi cacy endpoint was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months.
At 12 months, 94.5% of patients treated with 0.3 mg ranibizumab and 94.6% of those treated with 0.5 mg ranibizumab lost fewer than 15 letters from baseline visual acuity, compared with 62.2% in the sham injection group (P < 0.001 for the comparison of each dose with the sham injection group). At 24 months, 92.0%, 90.0%, and 52.9% of patients in the 0.3 mg ranibizumab, 0.5 mg ranibizumab, and sham injection group, respectively, had lost fewer than 15 letters of visual acuity (P < 0.001 for the comparison of each dose with the sham injection group). Furthermore, at both 12 and 24 months, approximately one-quarter of patients receiving 0.3 mg ranibizumab, and one-third of patients receiving 0.5 mg ranibizumab, had gained 15 or more letters in visual acuity, compared with 5.0% in the sham injection group at 12 months and 3.8% at 24 months. Figure 2A shows the mean change in visual acuity from baseline to month 24 in this trial. Only 0.8% of patients receiving 0.3 mg ranibizumab, and 1.2% of patients receiving 0.5 mg ranibizumab, had severe vision loss (lost 30 letters or more of visual acuity), compared with 14.3% of patients in the sham injection group. 25 There was no signifi cant difference between the three treatment groups in the rates of nonocular AEs. In terms of systemic anti-VEGF effects, the rates of hypertension and arterial thrombolic events were similar across groups. Nonocular haemorrhages were similar across all treatment groups in the fi rst year, but cumulative rates increased in all groups in the second year. At 24 months, nonocular haemorrhage rates were 9.2%, 8.8%, and 5.5% in the 0.3 mg ranibizumab, 0.5 mg ranibizumab, and sham injection groups, respectively; these differences were not signifi cant. Over the course of the study, fi ve patients who received ranibizumab experienced presumed endophthalmitis, and six patients receiving ranibizumab experienced serious uveitis. 25 A second phase III trial (ANCHOR-Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularisation) compared ranibizumab with verteporfi n PDT for the treatment of predominantly classic neovascular AMD. 26 In this study, 423 patients were randomised equally to receive monthly intravitreal injections of 0.3 mg ranibizumab or 0.5 mg ranibizumab plus sham verteporfi n therapy, or monthly sham injections plus active verteporfi n therapy. The primary endpoint was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. The results of this study support the fi ndings of MARINA, with 94.3% of patients receiving 0.3 mg ranibizumab and 96.4% of patients receiving 0.5 mg ranibizumab losing fewer than 15 letters, compared with 64.3% of patients receiving verteporfi n (P < 0.001 for each comparison). Visual acuity improved by at least 15 letters in 35.7% and 40.3% of patients in the 0.3 mg ranibizumab and 0.5 mg ranibizumab treatment groups, respectively, compared with 5.6% of patients in the verteporfi n treatment group (P < 0.001 for each comparison). Figure 2B shows the mean change in visual acuity from baseline to month 24 in this trial. Presumed endophthalmitis occurred in two patients (1.4%) and serious uveitis in one patient (0.7%). 26 The PIER study evaluated ranibizumab administered monthly for 3 months, followed by quarterly injections. 27 Using this schedule, ranibizumab provided a signifi cant visual acuity benefi t compared with sham treatment; however, treatment was less effective than the monthly schedule employed in MARINA and ANCHOR. 27 Visual acuity improvements were observed during the fi rst 3 months of the study; however, it then declined during the rest of the 24-month duration of the trial. A subgroup analysis demonstrated that although 40% of patients retained their initial visual acuity gain during the maintenance phase, the quarterly treatment schedule was not suitable for 60% of patients. Therefore, more frequent monitoring and dosing may be necessary to identify when treatment is needed. To address this question, a second phase IIIb study (SUSTAIN) is currently evaluating the effi cacy of 0.3 or 0.5 mg ranibizumab administered monthly for 3 consecutive months (loading phase), followed by monthly retreatment as required for 9 months. 28 Further doses are administered if visual acuity decreases by fi ve letters or more, or central retinal thickness (CRT) increases by 100 μm or more. Treatment was not given if visual acuity was 79 letters or more, or CRT was less than or equal to 225 μm. An interim analysis of 69 ranibizumab-naïve patients who had completed their 12-month visit showed a mean increase from baseline of 6.8 letters and a mean decrease in CRT of 74.4 μm at month 12, with patients receiving a mean of 5.3 injections (including the three loading-phase injections). Importantly, these improvements were stable from month 3. Therefore, although these results are only preliminary, it appears that good effi cacy outcomes can be achieved with ranibizumab with a lower monthly average frequency of treatment. 28 
Bevacizumab
Bevacizumab is a humanised monoclonal antibody to VEGF, designed for intravenous administration and currently approved in Europe for the treatment of colorectal cancer and advanced or metastatic renal cell cancer. Bevacizumab is derived from the same murine antibody as ranibizumab; however, it has a different structure and formulation and is not licensed for the treatment of AMD. Bevacizumab has been used on an off-label basis for the treatment of neovascular AMD; 29, 30 however, as no randomised clinical trials have been conducted, there is little fi rm evidence of either its safety or its effi cacy in this patient population. In the United States, the National Eye Institute and the National Institute of Health are collaborating on a multicentre clinical trial to compare the safety and effi cacy of ranibizumab and bevacizumab for the treatment of neovascular AMD. Likewise, in the UK, the National Health Service is running a similar trial. Results from these trials are expected in the next few years.
Switzerland
On 30 August 2006, Switzerland became the fi rst European country to approve Lucentis for the treatment of neovascular AMD. Although Lucentis has been fully reimbursed for the treatment of neovascular AMD in Switzerland since the beginning of 2007, treatment with Lucentis is limited to specialised centres and requires data monitoring for a national registry. The offi cial recommendations are to administer Lucentis by intravitreal injection once a month. If monthly injections are not feasible, treatment may be reduced to one injection every 3 months after the fi rst four injections, although this is not as effective.
Currently, it is estimated that Lucentis is used in Switzerland in around 95% of patients receiving intravitreal anti-VEGF treatment for neovascular AMD. In 2007, about 4000 patients with neovascular AMD received 12 560 intravitreal Lucentis injections. Treatment-naïve patients received on average 3.99 injections during the fi rst year.
In our centre, we have performed around 2800 Lucentis injections since we began using it for the treatment of neovascular AMD in March 2005. In the beginning, our treatment regimen included three monthly injections followed by dosing as required. Retreatment was initiated if visual acuity deteriorated or lesion activity increased, as shown by either optical coherence tomography (OCT) or by fl uorescein angiography; however, using this regimen we were not able to reproduce the exciting results of the ANCHOR or MARINA studies. Therefore, we are currently using a more aggressive approach to treatment (Fig. 3) : patients initially receive three monthly intravitreal injections of Lucentis, followed by maintenance dosage every 3 months in patients without active lesions and reinitiation of three monthly injections in patients with active lesions at follow-up visits. An active lesion is defi ned as new intra-or subretinal haemorrhages, intra-or subretinal fl uid accumulation on highresolution OCT, or leakage on fl uorescein angiography (Fig. 4) . First analysis confi rms that this approach may lead to a better visual outcome than the previously used regimen.
Future of Anti-VEGF Therapy
Anti-VEGF Therapy in Combination with PDT
Both ranibizumab and pegaptanib are currently being investigated in combination with PDT, with the aim of potentially reducing the number of intravitreal injections required. A small open-label study of seven patients treated with PDT followed by intravitreal pegaptanib 48 h later has recently been reported. 31 In this study, retreatment was indicated with pegaptanib every 6 weeks and with PDT every 12 weeks if fl uorescein angiography showed leakage or OCT detected intraretinal oedema. At 24 weeks, patients had an insignifi cant decrease in mean best-corrected visual acuity from 60.4 letters at baseline to 55.2 letters. The greatest linear dimension increased from 1280 to 2066 mm (P = 0.043), and the total area of CNV increased from 1.4 to 2.7 mm 2 (P = 0.05). Although these results are generally poor, the authors suggested that larger-scale controlled studies are required to ascertain whether PDT can reduce the number of intravitreal injections, and which antiangiogenic agent would provide the most potent combination with PDT. 31 Ranibizumab has also been investigated in combination with PDT. The FOCUS study was a 2-year multicentre, randomised, single-masked, controlled study to examine the safety and effi cacy of ranibizumab in combination with verteporfi n PDT in 162 patients with neovascular AMD. 32 Patients received monthly intravitreal ranibizumab or sham injections; all patients also received PDT on day 0, then quarterly as required. At month 24, 88% of patients receiving ranibizumab plus PDT had lost fewer than 15 letters of visual acuity, compared with 75% of patients receiving PDT alone (P < 0.05). In addition, 25% of patients in the combination therapy group had gained at least 15 letters, compared with 7% of patients treated with PDT alone (P < 0.05). Overall, patients receiving combination therapy showed less lesion growth and a larger reduction in CNV leakage and fl uid accumulation and required fewer PDT treatments than patients treated with PDT alone. The combination treatment group had higher rates of endophthalmitis (2.4%) and serious intraocular infl ammation (12.4%) than patients who received PDT alone (0% for each AE). The incidence of serious nonocular AEs was similar between the two groups. 32 In conclusion, the development of anti-VEGF therapies has revolutionised the treatment of AMD. The vision improvements associated with these therapies mean that blindness is no longer an inevitable consequence of this condition. Going forward, the combination of anti-VEGF therapies with PDT offers the potential for decreased frequency of injections or further improvement in treatment effi cacy. Furthermore, clinical trials of these agents in diabetic retinopathy and macular oedema (secondary to central and branch retinal vein occlusion, and diabetes mellitus) are also currently underway, suggesting that anti-VEGF therapies may have the potential to treat other debilitating eye conditions. 
